TBH Global Asset Management LLC Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

TBH Global Asset Management LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 13.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,734 shares of the biopharmaceutical company’s stock after selling 1,635 shares during the quarter. TBH Global Asset Management LLC’s holdings in Pfizer were worth $285,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Good Life Advisors LLC grew its position in shares of Pfizer by 27.1% during the fourth quarter. Good Life Advisors LLC now owns 71,410 shares of the biopharmaceutical company’s stock worth $1,895,000 after purchasing an additional 15,211 shares in the last quarter. Strata Wealth Advisors LLC grew its position in shares of Pfizer by 34.6% during the fourth quarter. Strata Wealth Advisors LLC now owns 15,162 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 3,897 shares in the last quarter. Convergence Investment Partners LLC grew its position in shares of Pfizer by 673.9% during the fourth quarter. Convergence Investment Partners LLC now owns 107,413 shares of the biopharmaceutical company’s stock worth $2,850,000 after purchasing an additional 93,533 shares in the last quarter. Plan Group Financial LLC grew its position in shares of Pfizer by 14.3% during the fourth quarter. Plan Group Financial LLC now owns 35,789 shares of the biopharmaceutical company’s stock worth $949,000 after purchasing an additional 4,472 shares in the last quarter. Finally, Allied Investment Advisors LLC grew its position in shares of Pfizer by 1.4% during the fourth quarter. Allied Investment Advisors LLC now owns 262,737 shares of the biopharmaceutical company’s stock worth $6,970,000 after purchasing an additional 3,534 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

NYSE:PFE opened at $25.86 on Friday. The firm has a market capitalization of $146.52 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The business has a 50 day simple moving average of $26.28 and a 200-day simple moving average of $27.44. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company earned $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.65%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Guggenheim reissued a “buy” rating and set a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.